Financial Perspectives in DVT Prophylaxis

Hospitals save a significant amount of money when they use a take home DVT prevention device. Circul8 is the only take home DVT prevention device available that incorporates Bluetooth technology and mobile device app for ease of use and patient monitoring.

The Clinical Studies Surrounding Financial Implications for DVT Prevention Methods

Venous thromboembolism (VTE) refers to the formation of blood clots within the veins of the body, most commonly the deep veins of the legs—deep vein thrombosis (DVT), and the complications that can happen when these clots break off into the circulation and get lodged in vessels elsewhere, most importantly in the pulmonary artery of the lungs. Pulmonary artery blockage can give rise to the life-threatening condition called pulmonary embolism (PE), which manifests as breathlessness, chest pain, and sudden death. The risk of developing VTE with major orthopedic surgery can be as high as 57%.
  • Acute VTE
  • Recurrent VTE
  • Post-thrombotic syndrome
  • Chronic pulmonary hypertension
  • Anticoagulation-related complications

Financial Perspectives in DVT Prophylaxis:

Newest generation tubeless cordless SCDs are most cost-effective.

1
Is VTE prophylaxis or no prophylaxis more cost-effective?
Evidence indicates that VTE prophylaxis is more cost-effective
2
Is chemical or mechanical prophylaxis more cost-effective?
Evidence indicates that mechanical prophylaxis is more cost-effective.
3
What type of mechanical prophylaxis is most cost-effective?
Newest generation tubeless cordless SCDs are most cost-effective.
Value analysis of Precision’s state-of-the-art Circul8 device

Cost savings on using prophylactic measures for VTE

VTE-related Per Patient Readmission Costs
VTE-related Incremental Cost
Per Patient Cost Savings with Prophylaxis
$11,862
$14,722
$2,663
Up to
$181
Result:
Mechanical Prophylaxis (IPCs)
more Cost-effective
  • Cost advantage per patient $369
  • Cost savings per 10,000-cohort $3.69 million

The ideal Prophylaxis should be:

  • Effective
  • Safe
  • Economical

The most cost-effective DVT prophylaxis: Circul8

Precision Medical Products provides a comprehensive DVT prevention program to hospitals, clinics, and ambulatory surgery centers. The program revolves around a state-of-the-art DVT prevention device—the Circul8. It is a mobile, battery-operated, tubeless, and cordless sequential compression device that is as safe as it is effective

Cumulative saving with a battery-operated SCD such as Circul8

is $550 per patient

REFERENCES

  • 1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338S–400S
  • 2. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016;137:3–10. doi:10.1016/j.thromres.2015.11.033
  • 3. Bernatz JT, Tueting JL, Anderson PA. Thirty-day readmission rates in orthopedics: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0123593. Published 2015 Apr 17. doi:10.1371/journal.pone.0123593
  • 4. Bernatz JT, Tueting JL, Hetzel S, Anderson PA. What Are the 30-day Readmission Rates Across Orthopaedic Subspecialties?. Clin Orthop Relat Res. 2016;474(3):838–847. doi:10.1007/s11999-015-4602-5
  • 5. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: An administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007;13(6):475-86
  • 6. Vekeman F, LaMori J, Laliberté F et al. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population. J Med Econ. 2011;14(3):324-334. doi:10.3111/13696998.2011.578698
  • 7. Vekeman F, LaMori J, Laliberté F et al. In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty. J Med Econ. 2012;15(4):644-653. doi:10.3111/13696998.2012.669438
  • 8. Bozic KJ, Ward L, Vail TP, Maze M. Bundled payments in total joint arthroplasty: targeting opportunities for quality improvement and cost reduction. Clin Orthop Relat Res. 2014;472:188–193. doi: 10.1007/s11999-013-3034-3
  • 9. Oster G. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA: The Journal of the American Medical Association. 1987;257(2):203-208. doi:10.1001/jama.257.2.203
  • 10. Bergqvist D, Lindgren B, Mätzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg. 1996; 83: 1548–1552
  • 11. Torrejon Torres R, Saunders R, Ho K. A comparative cost-effectiveness analysis of mechanical and pharmacological VTE prophylaxis after lower limb arthroplasty in Australia. J Orthop Surg Res. 2019;14(1). doi:10.1186/s13018-019-1124-y
  • 12. Saunders R, Comerota AJ, Ozols A, Torrejon Torres R, Ho KM. Intermittent pneumatic compression is a cost-effective method of orthopedic postsurgical venous thromboembolism prophylaxis. Clinicoecon Outcomes Res. 2018;10:231–241. Published 2018 Apr 19. doi:10.2147/CEOR.S157306
  • 13. Cost-Effectiveness of Venous Thromboembolism Prophylaxis With a New Mobile Device After Total Hip Arthroplasty. J Arthroplasty. 2012;27(8):1513-1517.e1. doi:10.1016/j.arth.2012.03.024
  • 14. Unexpected Risk from a Beneficial Device: Sequential Compression Devices and Patient Falls. PA PSRS Patient Saf Advis 2005 Sep;2(3):13-5
  • 15. Johnston J, Davis M. When Sequential-Compression Devices Cause Falls. AJN, American Journal of Nursing. 2008;108(4):37-38. doi:10.1097/01.naj.0000315258.46329.34
  • 16. Morello R, Barker A, Watts J et al. The extra resource burden of in-hospital falls: a cost of falls study. Med J Aust. 2015;203(9):367. doi:10.5694/mja15.00296